Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
Abstract
HS: Hidradenitis suppurativa IHS4: International Hidradenitis Suppurativa Severity Score System INTRODUCTION Hidradenitis suppurativa (HS) is a chronic, inflammatory, and debilitating skin disease, which usually occurs after puberty with painful, deepseated, inflammatory lesions in the apocrine glandbearing areas of the body. Several cases regarding flaring of inflammatory dermatoses after COVID vaccination have been recently described; particularly, Wack et al have discussed the safety and efficacy of COVID-19 vaccine in patients with immune-mediated inflammatory diseases. Moreover, it has been observed that quarantine and the reduction of physical activity during the pandemic may lead to a worsening of chronic skin conditions due to an increased mean body mass index among these patients. Herein we describe a case series of 5 patients, 2 men and 3 women, with a worsening of HS following COVID-19 vaccination. Each patient was staged according to the International Hidradenitis Suppurativa Severity Score System (IHS4) and had an increase of these values. All patient data regarding sex, age, comorbidities, type of vaccine received, current treatment for HS, and clinical scores variation are shown in Table I.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health. Reported size: 19 participants or records.
Read the paper
Related studies
- Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics
- Challenges in Chagas Disease Drug Development
- T Cell Specificity: A Great Challenge in Chagas Disease
- Benznidazole treatment leads to DNA damage in Trypanosoma cruzi and the persistence of rare widely dispersed non-replicative amastigotes in mice
- Rapid Molecular Detection of Terbinafine-resistant Dermatophytes
- Identifying novel drugs with new modes of action for neglected tropical fungal skin diseases (fungal skinNTDs) using an Open Source Drug discovery approach
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.